logo-loader
viewAvacta Group PLC

Avacta Group Plc making 'excellent progress' on lead programmes

Alastair Smith, chief executive of Avacta Group Plc (LON:AVCT), tells Proactive Investors their lead PD-L1 programme remains on track to deliver key pre-clinical milestones this year.

Smith says they're also making “excellent progress” with a second immuno-oncology research project, a LAG3 blockade, which can be combined with PD-L1 for improved efficacy.

Avacta, in its half-year results update, said its discovery programme continued to deliver a pipeline of binders to other important immuno-oncology targets for future partnering or development.

Quick facts: Avacta Group PLC

Price: 18.75 GBX

AIM:AVCT
Market: AIM
Market Cap: £32.99 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Avacta Group PLC named herein, including the promotion by the Company of Avacta Group PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Avacta Group heading into 'crucial year' for its cancer therapeutics programmes

Proactive Research analyst Ed Stacey says Avacta (LON:AVCT) is preparing for a crucial year in its cancer therapeutics programmes in 2020, with an opportunity now identified for a targeted chemotherapy programme to enter clinical trials during the first half. Stacey says alongside the recent...

on 23/10/19

2 min read